AMLX

In the past six months, Amylyx Pharmaceuticals experienced several significant stock events. Positive topline results from the Phase 3 LUCIDITY trial for avexitide in August 2026, showing a 55% reduction in severe hypoglycemic events, led to a nearly 79% increase in stock price. This was followed by analyst upgrades and price target revisions in August-September 2026. The company completed an upsized $500 million public offering in August 2026 and secured long-term manufacturing arrangements for avexitide in September 2026. However, shareholders experienced substantial dilution with a 41% increase in shares outstanding over the past year, and Q2 2026 earnings in August 2026 missed consensus estimates, causing a slight premarket decline.